NT5E and inflammatory bowel disease: Our findings demonstrated that ERCs were a prolific candidate for IBD management that provide a CD73+ cellular environment locally by intraperitoneal injection in the inflammation process, which facilitates the hydrolysis of pro-inflammatory ATP into immunosuppressive ADO.